Appendix A - Search terms used in the PROMOTION registry

Bladder cancer RCTs

("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR “patient outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR “psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported symptom” OR “patient reported outcomes” OR pain OR fatigue OR “patient reported outcome” OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR “symptom assessment” OR “functional status” OR sexual OR functioning) AND bladder

Breast cancer RCTs

("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR “patient outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR “psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported symptom” OR “patient reported outcomes” OR pain OR fatigue OR “patient reported outcome” OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR “symptom assessment” OR “functional status” OR sexual OR functioning OR “body image” OR “sexual”) AND (“breast” OR “breast cancer” OR “breast carcinoma” OR “breast tumour” OR “breast tumor”)

Colorectal + anal cancers RCTs

("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR “patient outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR “psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported symptom” OR “patient reported outcomes” OR pain OR fatigue OR “patient reported outcome” OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR “symptom assessment” OR “symptom distress” OR “functional status”) AND (colon OR colorectal OR rectum OR rectal OR “hepatic metastases” OR “liver metastases” OR "anal cancer")

Gynaecological cancers RCTs

(gynecological OR GYN OR cervical OR ovarian OR endometrial OR vulvar OR vaginal OR uterine OR hysterectomy OR “fallopian tubes” OR clitoris OR vulva OR vulval OR vaginal OR endometrium OR ovary OR cervix OR uterus OR ovaries OR vagina OR pelvis OR “germ cell” OR genital OR “reproductive system” OR cervical OR “cone biopsy” OR conization OR oophorectomy OR vulvectomy) AND ("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR “patient outcomes” OR “depression” OR “anxiety” OR “emotional” OR “social” OR “psychosocial” OR “psychological” OR “distress” OR “social functioning” OR “social wellbeing” OR “patient reported symptom” OR “patient reported outcomes” OR pain OR fatigue OR “patient reported outcome” OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR “symptom distress” OR “symptom burden” OR “symptom assessment” OR “symptom distress” OR “functional status” OR sexuality OR libido OR “body image” OR arousal OR orgasm OR “sexual desire” OR excitement OR vaginitis OR lubrication OR femininity OR appearance OR intimacy OR intercourse OR relationship OR sexual OR bloating OR sex OR psychosexual OR sexuality OR dyspareunia OR “abdominal swelling” OR constipation OR “vaginal bleeding” OR reconstructive OR “plastic surgery” OR reconstruction) AND (leiomyosarcoma OR sarcoma OR cancer OR malignant OR adenocarcinoma OR malignancy OR carcinoma OR neoplasm OR tumor OR tumour)
Lung cancer RCTs

("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR "patient outcomes" OR "depression" OR "anxiety" OR "emotional" OR "social" OR "psychosocial" OR "psychological" OR "distress" OR "social functioning" OR "social wellbeing" OR "patient reported symptom" OR "patient reported outcomes" OR "pain" OR "fatigue" OR "patient reported outcome" OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR "symptom distress" OR "symptom burden" OR "symptom assessment" OR "functional status" OR "sexual" OR "functioning") AND ("lung cancer" OR "lung carcinoma" OR "lung tum*" OR "lung" OR "non-small")

Prostate cancer RCTs

("quality of life" OR "health related quality of life" OR "health status" OR "health outcomes" OR "patient outcomes" OR "depression" OR "anxiety" OR "emotional" OR "social" OR "psychosocial" OR "psychological" OR "distress" OR "social functioning" OR "social wellbeing" OR "patient reported symptom" OR "patient reported outcomes" OR "pain" OR "fatigue" OR "patient reported outcome" OR "PRO" OR "PROs" OR "HRQL" OR "QOL" OR "HRQOL" OR "symptom distress" OR "symptom burden" OR "symptom assessment" OR "functional status" OR "sexual" OR "functioning") AND prostate
### Classification of study endpoints*

<table>
<thead>
<tr>
<th>Study endpoint</th>
<th>Classified as</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall survival</td>
<td>Overall survival</td>
</tr>
<tr>
<td>Progression-free survival</td>
<td>Progression-free survival</td>
</tr>
<tr>
<td>Event-free survival</td>
<td></td>
</tr>
<tr>
<td>Disease-free survival</td>
<td></td>
</tr>
<tr>
<td>Time to progression</td>
<td></td>
</tr>
<tr>
<td>Duration of response</td>
<td></td>
</tr>
<tr>
<td>Toxicity</td>
<td>Toxicity</td>
</tr>
<tr>
<td>Safety</td>
<td></td>
</tr>
<tr>
<td>Feasibility</td>
<td></td>
</tr>
<tr>
<td>Maximum-tolerated dose</td>
<td></td>
</tr>
<tr>
<td>Response</td>
<td>Efficacy</td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
</tr>
<tr>
<td>Time to response</td>
<td></td>
</tr>
<tr>
<td>Engraftment</td>
<td></td>
</tr>
<tr>
<td>Time to failure</td>
<td></td>
</tr>
<tr>
<td>Health care utilization</td>
<td>Healthcare utilization</td>
</tr>
<tr>
<td>Health economics</td>
<td></td>
</tr>
<tr>
<td>Laboratory parameters</td>
<td>Biological parameters</td>
</tr>
<tr>
<td>Genetic parameters</td>
<td></td>
</tr>
<tr>
<td>Tumor biology</td>
<td></td>
</tr>
<tr>
<td>Completion of planes treatment</td>
<td>Completion of treatment</td>
</tr>
<tr>
<td>Achieved dose intensity</td>
<td></td>
</tr>
<tr>
<td>Compliance to treatment</td>
<td></td>
</tr>
</tbody>
</table>

Appendix C

References of studies with a high-quality PRO reporting


39. Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive
Results from a Phase II Randomized Trial. Prednisone Versus Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer. Khalaf DJ, Sunderl


